We are live on ! Find out more
KYTX icon

Kyverna Therapeutics
KYTX

90 hedge funds and large institutions have $762M invested in Kyverna Therapeutics in 2024 Q1 according to their latest regulatory filings, with 90 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

71.21% more ownership

Funds ownership: 0% → 71.21% (+71%)

99% less call options, than puts

Call options by funds: $5K | Put options by funds: $514K

Holders
90
Holders Change
+90
Holders Change %
–
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
90
Increased
–
Reduced
–
Closed
–
Calls
$5K
Puts
$514K
Net Calls
-$509K
Net Calls Change
-$509K

Top Buyers

Rank Fund Capital Flow
1
VVA
Vida Ventures Advisors
Massachusetts
+$126M
2
NV
Northpond Ventures
Maryland
+$90.8M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$88.3M
4
RI
RTW Investments
New York
+$51.7M
5
DM
Deerfield Management
New York
+$40.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
APM
26
Avidity Partners Management
Texas
$5.03M +$5.65M +202,333 New
AG
27
Artal Group
Luxembourg
$4.97M +$5.58M +200,000 New
RSCM
28
Rock Springs Capital Management
Maryland
$4.45M +$4.99M +178,963 New
Geode Capital Management
29
Geode Capital Management
Massachusetts
$4.28M +$4.81M +172,236 New
CCM
30
Cutter Capital Management
New York
$4.14M +$4.65M +166,514 New
Marshall Wace
31
Marshall Wace
United Kingdom
$3.87M +$4.35M +155,755 New
CC
32
Casdin Capital
New York
$3.73M +$4.19M +150,000 New
GPP
33
Great Point Partners
Connecticut
$3.73M +$4.19M +150,000 New
PA
34
Perceptive Advisors
New York
$3.73M +$4.19M +150,000 New
Walleye Capital
35
Walleye Capital
New York
$3.73M +$4.19M +150,000 New
UBS AM
36
UBS AM
Illinois
$2.63M +$2.95M +105,900 New
LP
37
LMR Partners
United Kingdom
$2.6M +$2.92M +104,814 New
Blackstone Inc
38
Blackstone Inc
New York
$2.48M +$2.79M +100,000 New
Pictet Asset Management
39
Pictet Asset Management
Switzerland
$2.48M +$2.79M +100,000 New
Squarepoint
40
Squarepoint
New York
$2.2M +$2.47M +88,423 New
Charles Schwab
41
Charles Schwab
California
$2.11M +$2.37M +84,880 New
Invesco
42
Invesco
Georgia
$1.88M +$2.12M +75,865 New
ACH
43
ArrowMark Colorado Holdings
Colorado
$1.74M +$1.95M +70,000 New
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$1.72M +$1.93M +69,237 New
Alyeska Investment Group
45
Alyeska Investment Group
Illinois
$1.61M +$1.81M +65,000 New
PD
46
Point72 (DIFC)
United Arab Emirates
$1.51M +$1.7M +60,800 New
Citigroup
47
Citigroup
New York
$1.48M +$1.66M +59,666 New
State Street
48
State Street
Massachusetts
$1.25M +$1.41M +50,400 New
Hudson Bay Capital Management
49
Hudson Bay Capital Management
Connecticut
$1.24M +$1.4M +50,000 New
PBA
50
Paradigm Biocapital Advisors
New York
$1.24M +$1.4M +50,000 New
1
2
3 4

KYTX Hedge Fund Activity: Q1 2024 in Review

90 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q1 2024, worth a combined $762M.

Buyers outnumbered sellers: 90 funds opened new KYTX positions and 0 closed out — a net gain of 90 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vida Ventures Advisors, opening a new position worth an estimated $126M.

  • 90 institutional investors held Kyverna Therapeutics (KYTX) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $762M of Kyverna Therapeutics stock for Q1 2024.
  • 90 funds opened new Kyverna Therapeutics positions in Q1 2024 and 0 closed out, a net change of +90 holders.
  • The largest Kyverna Therapeutics buyer in Q1 2024 was Vida Ventures Advisors, an estimated $126M added.

Based on aggregated 13F filings for Q1 2024.